Additional file 2: Figure S2. of Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial
Robert Canter
Steven Grossenbacher
Jennifer Foltz
Ian Sturgill
Jiwon Park
Jesus Luna
Michael Kent
William Culp
Mingyi Chen
Jaime Modiano
Arta Monjazeb
Dean Lee
William Murphy
10.6084/m9.figshare.5715319.v1
https://springernature.figshare.com/articles/figure/Additional_file_2_Figure_S2_of_Radiotherapy_enhances_natural_killer_cell_cytotoxicity_and_localization_in_pre-clinical_canine_sarcomas_and_first-in-dog_clinical_trial/5715319
Validation of ALDH as a CSC Marker in Dog PDX Tumors. A. A dog sarcoma PDX tumor was allowed to grow to ~ 20 mm in maximal dimension. The tumor was then excised and digested into single cell suspension. B. Tumor cells were sorted by flow cytometry into ALDHbright and ALDHdim populations. 2 × 105 purified cells were implanted subcutaneously into contralateral flanks of NSG mice (N = 4) and allowed to grow. ALDHbright cells established tumors faster and were more rapidly fatal. * P < 0.05 via one-way ANOVA with Tukey’s post-test. C. Representative photograph showing difference in tumor formation between ALDHbright and ALDHdim sarcoma PDX #465049 cells implanted subcutaneously in NSG mice. (TIFF 890 kb)
2017-12-19 05:00:00
Natural killer cells
Adoptive immunotherapy
Radiotherapy
Sarcoma
Canine